Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) SVP Robert E. Landry sold 526 shares of the company’s stock in a transaction on Tuesday, August 8th. The shares were sold at an average price of $472.19, for a total value of $248,371.94. Following the completion of the sale, the senior vice president now owns 9,099 shares of the company’s stock, valued at $4,296,456.81. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Regeneron Pharmaceuticals, Inc. (REGN) traded up 0.94% during midday trading on Wednesday, reaching $474.09. The company’s stock had a trading volume of 979,959 shares. Regeneron Pharmaceuticals, Inc. has a 1-year low of $325.35 and a 1-year high of $543.55. The company has a 50 day moving average of $499.39 and a 200-day moving average of $422.69. The company has a market capitalization of $50.05 billion, a P/E ratio of 57.39 and a beta of 1.66.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $4.17 EPS for the quarter, topping the Zacks’ consensus estimate of $2.67 by $1.50. The company had revenue of $1.47 billion for the quarter, compared to analysts’ expectations of $1.36 billion. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. The firm’s quarterly revenue was up 21.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.82 earnings per share. Equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post $14.84 earnings per share for the current fiscal year.

WARNING: This report was first reported by Daily Political and is owned by of Daily Political. If you are accessing this report on another website, it was stolen and republished in violation of United States & international trademark and copyright legislation. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/08/09/insider-selling-regeneron-pharmaceuticals-inc-nasdaqregn-svp-sells-526-shares-of-stock.html.

Hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. boosted its position in shares of Regeneron Pharmaceuticals by 3,331.5% in the first quarter. BlackRock Inc. now owns 6,146,861 shares of the biopharmaceutical company’s stock worth $2,381,971,000 after buying an additional 5,967,733 shares in the last quarter. Jennison Associates LLC boosted its position in Regeneron Pharmaceuticals by 74.1% in the second quarter. Jennison Associates LLC now owns 1,292,863 shares of the biopharmaceutical company’s stock valued at $634,977,000 after buying an additional 550,247 shares during the period. Janus Capital Management LLC boosted its position in Regeneron Pharmaceuticals by 58.5% in the first quarter. Janus Capital Management LLC now owns 1,317,162 shares of the biopharmaceutical company’s stock valued at $510,406,000 after buying an additional 486,119 shares during the period. Wellington Management Group LLP boosted its position in Regeneron Pharmaceuticals by 7.9% in the first quarter. Wellington Management Group LLP now owns 6,135,559 shares of the biopharmaceutical company’s stock valued at $2,377,590,000 after buying an additional 446,850 shares during the period. Finally, Clearbridge Investments LLC boosted its position in Regeneron Pharmaceuticals by 55.2% in the first quarter. Clearbridge Investments LLC now owns 690,254 shares of the biopharmaceutical company’s stock valued at $267,480,000 after buying an additional 245,531 shares during the period. Institutional investors own 66.70% of the company’s stock.

Several analysts have issued reports on REGN shares. Canaccord Genuity upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and upped their target price for the company from $375.00 to $484.00 in a report on Friday, May 5th. Vetr cut Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating and set a $408.86 target price for the company. in a report on Monday, May 1st. Zacks Investment Research cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 4th. Piper Jaffray Companies upped their target price on Regeneron Pharmaceuticals from $446.00 to $557.00 and gave the company an “overweight” rating in a report on Tuesday, June 20th. Finally, Jefferies Group LLC restated a “hold” rating and issued a $357.00 target price on shares of Regeneron Pharmaceuticals in a report on Wednesday, April 12th. Two research analysts have rated the stock with a sell rating, fourteen have given a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $489.35.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Insider Buying and Selling by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.